Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The main objective of the study will be to test the hypothesis that treatment with
Liraglutide will decrease ER stress and adipose tissue in obese patients with type 2
diabetes. Experimental Approach: The investigators will use a prospective, single blind,
placebo controlled study design to study 12 obese patients with type 2 diabetes mellitus
(T2DM). 6 patients will first receive Liraglutide for 24 weeks followed by placebo for 12
weeks. The other 6 patients will first receive placebo for 12 weeks followed by Liraglutide
for 24 weeks.
Measurements: The investigators will determine glycemic control (with HbA1c), body
composition (bioelectric impedance analysis), insulin sensitivity (with
hyperinsulinemic-euglycemic clamps), insulin secretion (with oral glucose tolerance testing),
energy balance (calories in vs. calories out), plasma lipid levels and obtain subcutaneous
fat biopsies to determine ER stress response markers before and after placebo and before and
after Liraglutide treatment.